This study aimed to define factors associated with relapse among responders to pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy in chronic hepatitis C.
Methods
A cohort of genotype 1b chronic hepatitis C patients treated with PEG-IFN plus RBV and who had an undetectable HCV RNA by week 12 (n=951) were randomly assigned to model derivation (n=636) or internal validation (n=315) groups. An independent cohort (n=598) were used for an external validation. A decision tree model for relapse was explored using data mining analysis.
Results
The data mining analysis defined five subgroups of patients with variable rates of relapse ranging from 13% to 52%. The reproducibility of the model was confirmed by internal and external validations (r2=0.79 and 0.83, respectively). Patients with undetectable HCV RNA at week 4 had the lowest risk of relapse (13%), followed by patients <60 years with undetectable HCV RNA at week 5–12 who received ≥3.0 g/kg of body weight of RBV (16%). Older patients with a total RBV dose <3.0 g/ kg had the highest risk of relapse (52%). Higher RBV dose beyond 3.0 g/kg was associated with further decrease of relapse rate among patients <60 years (up to 11%) but not among older patients whose relapse rate remained stable around 30%.
Conclusions
Data mining analysis revealed that time to HCV RNA negativity, age and total RBV dose was associated with relapse. To prevent relapse, ≥3.0 g/kg of RBV should be administered. Higher dose of RBV may be beneficial in patients <60 years.
References
1.
StraderD.B., WrightT., ThomasD.L., SeeffL.B.Diagnosis, management, and treatment of hepatitis C. Hepatology2004; 39: 1147–1171.
2.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
3.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
4.
DavisG.L., WongJ.B., McHutchisonJ.G., MannsM.P., HarveyJ., AlbrechtJ.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology2003; 38: 645–652.
5.
LeeS.S., FerenciP.Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther2008; 13Suppl 1: 9–16.
6.
NamikiI., NishiguchiS., HinoK.Management of hepatitis C: report of the consensus meeting at the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res2010; 40: 347–368.
YuM.L., DaiC.Y., HuangJ.F.Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology2008; 47: 1884–1893.
9.
BergT., von WagnerM., NasserS.Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology2006; 130: 1086–1097.
10.
Sánchez-TapiasJ.M., DiagoM., EscartinP.Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology2006; 131: 451–460.
11.
FerenciP., LaferlH., ScherzerT.M.Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology2010; 138: 503–512.e1.
12.
ButiM., LurieY., ZakharovaN.G.Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology2010; 52: 1201–1207.
13.
PearlmanB.L., EhlebenC., SaifeeS.Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology2007; 46: 1688–1694.
14.
TanakaY., NishidaN., SugiyamaM.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet2009; 41: 1105–1109.
15.
SuppiahV., MoldovanM., AhlenstielG.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet2009; 41: 1100–1104.
16.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature2009; 461: 399–401.
17.
KurosakiM., TanakaY., NishidaN.Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol2011; 54: 439–448.
GarzottoM., ParkY., Mongoue-TchokoteS.Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. Cancer2005; 104: 1911–1917.
20.
MiyakiK., TakeiI., WatanabeK., NakashimaH., OmaeK.Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. J Epidemiol2002; 12: 243–248.
21.
AverbookB.J., FuP., RaoJ.S., MansourE.G.A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. Surgery2002; 132: 589–604.
22.
LeiterU., BuettnerP.G., EigentlerT.K., GarbeC.Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German dermatological society. J Clin Oncol2004; 22: 3660–3667.
23.
ValeraV.A., WalterB.A., YokoyamaN.Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. Ann Surg Oncol2007; 14: 34–40.
24.
ZlobecI., SteeleR., NigamN., ComptonC.C.A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res2005; 11: 5440–5443.
25.
BaquerizoA., AnselmoD., ShackletonC.Phosphorus ans an early predictive factor in patients with acute liver failure. Transplantation2003; 75: 2007–2014.
26.
KurosakiM., MatsunagaK., HirayamaI.A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res2010; 40: 251–260.
27.
KurosakiM., SakamotoN., IwasakiM.Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol2011; 46: 401–409.
28.
KurosakiM., SakamotoN., IwasakiM.Sequences in the interferon sensitivity determining region and core region of hepatitis C virus impact pretreatment prediction of response to peg-interferon plus ribavirin: data mining analysis. J Med Virol2011; 83: 445–452.
29.
LeBlancM., CrowleyJ.A review of tree-based prognostic models. Cancer Treat Res1995; 75: 113–124.
30.
SegalM.R., BlochD.A.A comparison of estimated proportional hazards models and regression trees. Stat Med1989; 8: 539–550.
31.
McHutchisonJ.G., MannsM., PatelK.Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology2002; 123: 1061–1069.
32.
ShiffmanM.L., GhanyM.G., MorganT.R.Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology2007; 132: 103–112.
33.
HiramatsuN., OzeT., YakushijinT.Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat2009; 16: 586–594.
34.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
35.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
